Table 4.
Characteristics of Patients in Cohort 3. Characteristics of patients referred for evaluation of symptoms following 1st dose mRNA COVID-19 vaccine are shown. All patients received 2nd dose. Both columns show symptoms and treatment following 1st dose. Details regarding 2nd dose symptoms and treatment are reported in the manuscript.
| Characteristics | All patients (n = 44) | Patients with symptoms after second dose (n = 4) |
|---|---|---|
| Age in y, median (range) | 45 (24-78) | 44 (34-52) |
| Female sex at birth, n (%) | 39 (89) | 4 (100) |
| Race and Ethnicity, n (%) White Hispanic or Latino Black Asian American Indian Multiracial Other or declined or unknown |
22 (50) 6 (14) 1 (2) 10 (23) — 1 (2) 4 (9) |
— 1 (25) — 2 (50) — — 1 (25) |
| Primary language, n (%) English Mandarin |
43 (98) 1 (2) |
4 (100) — |
| Documented allergies in EMR, median (range) | 2 (0-11) | 6 (5-11) |
| Comorbidities Drug allergy Food allergy Environmental allergy Asthma History of anaphylaxis Atopic dermatitis Urticaria/angioedema Anxiety |
25 (57) 16 (36) 27 (61) 22 (50) 8 (18) 8 (18) 5 (11) 24 (55) |
4 (100) 3 (75) 4 (100) 4 (100) 3 (75) 2 (50) 1 (25) 4 (100) |
| Symptoms onset <30 min (Pfizer 19, Moderna 11) 30-60 min (Pfizer 5, Moderna 4) 1-4 h (Pfizer 2, Moderna 1) 5-12 h (Pfizer 1, Moderna 1) |
— 30 (68) 9 (20) 3 (7) 2 (5) |
— 4 (100) — — — |
| Symptoms Cutaneous Lower respiratory Cardiovascular Neurologic Gastrointestinal Upper airway Tongue/throat sensation |
— 31 (70) 10 (23) 5 (11) 15 (34) 6 (14) 3 (7) 15 (34) |
— 4 (100) 2 (50) — — — — 3 (75) |
| Treatment Antihistamines (H1) Corticosteroids Intramuscular epinephrine ED visit only Hospitalization |
— 14 (32) 2 (5) 6 (14) 12 (27) 1 (2) |
— 4 (100) — 2 (50) 2 (50) 1 (25) |
Abbreviations: COVID-19, coronavirus disease 2019; ED, emergency department; EMR, electronic medical record; mRNA, messenger RNA.